Novartis prepares for FDA submission for its chronic hives treatment

Novartis prepares for FDA submission for its chronic hives treatment

Submitted by admin on August 9, 2023 - 10:15am
Source: 
Clinical Trials Arena
News Tags: 
Novartis
remibrutinib
chronic hives
FDA
Headline: 
Novartis prepares for FDA submission for its chronic hives treatment
snippet: 

Following the Phase III trials for remibrutinib meeting their primary endpoints, Novartis plans for regulatory submissions in 2024.

Do Not Allow Advertisers to Use My Personal information